Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Medications for unhealthy alcohol use: across the spectrum.

O'Malley SS, O'Connor PG.

Alcohol Res Health. 2011;33(4):300-12. Review.

2.

Pharmacogenetic approaches to the treatment of alcohol addiction.

Heilig M, Goldman D, Berrettini W, O'Brien CP.

Nat Rev Neurosci. 2011 Oct 20;12(11):670-84. doi: 10.1038/nrn3110. Review.

3.

A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients.

Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R; NCIG 001 Study Group.

Alcohol Clin Exp Res. 2012 Mar;36(3):406-16. doi: 10.1111/j.1530-0277.2011.01649.x. Epub 2011 Sep 26.

4.

The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders.

Anton RF, Litten RZ, Falk DE, Palumbo JM, Bartus RT, Robinson RL, Kranzler HR, Kosten TR, Meyer RE, O'Brien CP, Mann K, Meulien D.

Neuropsychopharmacology. 2012 Jan;37(2):402-11. doi: 10.1038/npp.2011.182. Epub 2011 Sep 7.

5.

A dearth of new meds.

Kaitin KI, Milne CP.

Sci Am. 2011 Aug;305(2):16. No abstract available.

PMID:
21827111
6.

Reengineering translational science: the time is right.

Collins FS.

Sci Transl Med. 2011 Jul 6;3(90):90cm17. doi: 10.1126/scitranslmed.3002747.

7.

How to revive breakthrough innovation in the pharmaceutical industry.

Munos BH, Chin WW.

Sci Transl Med. 2011 Jun 29;3(89):89cm16. doi: 10.1126/scitranslmed.3002273.

PMID:
21715677
8.

Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists.

Lazary J, Juhasz G, Hunyady L, Bagdy G.

Trends Pharmacol Sci. 2011 May;32(5):270-80. doi: 10.1016/j.tips.2011.02.013. Epub 2011 Apr 16. Review.

PMID:
21497918
9.

Adoption and implementation of medications in addiction treatment programs.

Knudsen HK, Abraham AJ, Roman PM.

J Addict Med. 2011 Mar;5(1):21-7. doi: 10.1097/ADM.0b013e3181d41ddb.

10.

Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.

Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD.

Am J Psychiatry. 2011 Mar;168(3):265-75. doi: 10.1176/appi.ajp.2010.10050755. Epub 2011 Jan 19. Erratum in: Am J Psychiatry. 2011 Jul;168(7):756.

11.

A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype.

Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, Arias AJ, Pettinati H, Oncken C.

J Clin Psychopharmacol. 2011 Feb;31(1):22-30. doi: 10.1097/JCP.0b013e31820465fa. Erratum in: J Clin Psychopharmacol. 2011 Oct;31(5):576.

12.

Selective Modulation of Gq/Gs pathways by Naphtho Pyrano Pyrimidines as antagonists of the Neuropeptide S Receptor.

McCoy JG, Marugan JJ, Liu K, Zheng W, Southall N, Huang W, Heilig M, Austin CP.

ACS Chem Neurosci. 2010 Aug 18;1(8):559-574.

13.

Is pharma running out of brainy ideas?

Miller G.

Science. 2010 Jul 30;329(5991):502-4. doi: 10.1126/science.329.5991.502. No abstract available.

PMID:
20671165
14.

Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.

Falk D, Wang XQ, Liu L, Fertig J, Mattson M, Ryan M, Johnson B, Stout R, Litten RZ.

Alcohol Clin Exp Res. 2010 Dec;34(12):2022-34. doi: 10.1111/j.1530-0277.2010.01290.x.

PMID:
20659066
15.

Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate.

Kiefer F, Witt SH, Frank J, Richter A, Treutlein J, Lemenager T, Nöthen MM, Cichon S, Batra A, Berner M, Wodarz N, Zimmermann US, Spanagel R, Wiedemann K, Smolka MN, Heinz A, Rietschel M, Mann K.

Pharmacogenomics J. 2011 Oct;11(5):368-74. doi: 10.1038/tpj.2010.51. Epub 2010 Jun 29.

PMID:
20585342
16.

Individual differences in prefrontal cortex function and the transition from drug use to drug dependence.

George O, Koob GF.

Neurosci Biobehav Rev. 2010 Nov;35(2):232-47. doi: 10.1016/j.neubiorev.2010.05.002. Epub 2010 May 20. Review.

17.

Pharmacogenetics of alcohol and alcohol dependence treatment.

Kranzler HR, Edenberg HJ.

Curr Pharm Des. 2010;16(19):2141-8. Review.

18.

A genetic determinant of the striatal dopamine response to alcohol in men.

Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, Sommer WH, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M.

Mol Psychiatry. 2011 Aug;16(8):809-17. doi: 10.1038/mp.2010.56. Epub 2010 May 18.

19.

Alcohol biomarkers in applied settings: recent advances and future research opportunities.

Litten RZ, Bradley AM, Moss HB.

Alcohol Clin Exp Res. 2010 Jun;34(6):955-67. doi: 10.1111/j.1530-0277.2010.01170.x. Epub 2010 Apr 5.

PMID:
20374219
20.

A call for sharing: adapting pharmaceutical research to new realities.

Munos BH, Chin WW.

Sci Transl Med. 2009 Dec 2;1(9):9cm8. doi: 10.1126/scitranslmed.3000155.

PMID:
20368187

Supplemental Content

Support Center